Galen Missig1, Linda Mei1, Margaret A Vizzard1, Karen M Braas1, James A Waschek2, Kerry J Ressler3, Sayamwong E Hammack4, Victor May5. 1. Department of Neurological Sciences, Burlington, Vermont. 2. Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. 3. Division of Depression and Anxiety, McLean Hospital-Harvard Medical School, Belmont, Massachusetts. 4. Department of Psychological Science, University of Vermont College of Medicine, Burlington, Vermont. 5. Department of Neurological Sciences, Burlington, Vermont. Electronic address: victor.may@uvm.edu.
Abstract
BACKGROUND: Chronic pain and stress-related psychopathologies, such as depression and anxiety-associated abnormalities, are mutually reinforcing; however, the neuronal circuits and mechanisms that underlie this reinforcement are still not well understood. Pituitary adenylate cyclase-activating polypeptide (PACAP; Adcyap1) and its cognate PAC1 receptor (Adcyap1r1) are expressed in peripheral nociceptive pathways, participate in anxiety-related responses and have been have been linked to posttraumatic stress disorder and other mental health afflictions. METHODS: Using immunocytochemistry, pharmacological treatments and behavioral testing techniques, we have used a rodent partial sciatic nerve chronic constriction injury model (n = 5-8 per group per experiment) to evaluate PACAP plasticity and signaling in nociceptive and stress-related behaviors. RESULTS: We show that chronic neuropathic pain increases PACAP expression at multiple tiers along the spinoparabrachioamygdaloid tract. Furthermore, chronic constriction injury bilaterally augments nociceptive amygdala (in the central nucleus of the amygdala [CeA]) PACAP immunoreactivity, extracellular signal-regulated kinase phosphorylation, and c-Fos activation, in parallel with heightened anxiety-like behavior and nociceptive hypersensitivity. Acute CeA infusions with the PACAP receptor antagonist PACAP(6-38) blocked chronic constriction injury-induced behavioral responses. Additionally, pretreatments with inhibitors of mitogen-activated protein kinase enzymes or endocytosis to block endosomal PACAP receptor extracellular signal-regulated kinase signaling attenuated PACAP-induced CeA neuronal activation and nociceptive responses. CONCLUSIONS: Our data suggest that chronic pain-induced PACAP neuroplasticity and signaling in spinoparabrachioamygdaloid projections have an impact on CeA stress- and nociception-associated maladaptive responses, which can be ameliorated upon receptor antagonism even during injury progression. Thus, the PACAP pathway provides for an important mechanism underlying the intersection of stress and chronic pain pathways via the amygdala.
BACKGROUND:Chronic pain and stress-related psychopathologies, such as depression and anxiety-associated abnormalities, are mutually reinforcing; however, the neuronal circuits and mechanisms that underlie this reinforcement are still not well understood. Pituitary adenylate cyclase-activating polypeptide (PACAP; Adcyap1) and its cognate PAC1 receptor (Adcyap1r1) are expressed in peripheral nociceptive pathways, participate in anxiety-related responses and have been have been linked to posttraumatic stress disorder and other mental health afflictions. METHODS: Using immunocytochemistry, pharmacological treatments and behavioral testing techniques, we have used a rodent partial sciatic nerve chronic constriction injury model (n = 5-8 per group per experiment) to evaluate PACAP plasticity and signaling in nociceptive and stress-related behaviors. RESULTS: We show that chronic neuropathic pain increases PACAP expression at multiple tiers along the spinoparabrachioamygdaloid tract. Furthermore, chronic constriction injury bilaterally augments nociceptive amygdala (in the central nucleus of the amygdala [CeA]) PACAP immunoreactivity, extracellular signal-regulated kinase phosphorylation, and c-Fos activation, in parallel with heightened anxiety-like behavior and nociceptive hypersensitivity. Acute CeA infusions with the PACAP receptor antagonist PACAP(6-38) blocked chronic constriction injury-induced behavioral responses. Additionally, pretreatments with inhibitors of mitogen-activated protein kinase enzymes or endocytosis to block endosomal PACAP receptor extracellular signal-regulated kinase signaling attenuated PACAP-induced CeA neuronal activation and nociceptive responses. CONCLUSIONS: Our data suggest that chronic pain-induced PACAP neuroplasticity and signaling in spinoparabrachioamygdaloid projections have an impact on CeA stress- and nociception-associated maladaptive responses, which can be ameliorated upon receptor antagonism even during injury progression. Thus, the PACAP pathway provides for an important mechanism underlying the intersection of stress and chronic pain pathways via the amygdala.
Authors: Kimberly R Lezak; Carolyn W Roman; Karen M Braas; Kristin C Schutz; William A Falls; Jay Schulkin; Victor May; Sayamwong E Hammack Journal: J Mol Neurosci Date: 2014-03-12 Impact factor: 3.444
Authors: Bálint Botz; András Imreh; Katalin Sándor; Krisztián Elekes; János Szolcsányi; Dóra Reglődi; John P Quinn; James Stewart; Andreas Zimmer; Hitoshi Hashimoto; Zsuzsanna Helyes Journal: Peptides Date: 2013-03-13 Impact factor: 3.750
Authors: Galen Missig; Carolyn W Roman; Margaret A Vizzard; Karen M Braas; Sayamwong E Hammack; Victor May Journal: Neuropharmacology Date: 2014-07-03 Impact factor: 5.250
Authors: Victor May; Thomas R Buttolph; Beatrice M Girard; Todd A Clason; Rodney L Parsons Journal: Am J Physiol Cell Physiol Date: 2014-04-02 Impact factor: 4.249
Authors: Jacqueline Ojala; Katharine Tooke; Harrison Hsiang; Beatrice M Girard; Victor May; Margaret A Vizzard Journal: J Mol Neurosci Date: 2018-09-27 Impact factor: 3.444
Authors: Valentina Sabino; Pietro Cottone; Antonio Ferragud; Clara Velazquez-Sanchez; Margaret A Minnig Journal: Neuropsychopharmacology Date: 2020-11-16 Impact factor: 7.853